Funding for this research was provided by:
F Hoffmann-La Roche/Genentech
Received: 17 August 2018
Accepted: 15 August 2019
First Online: 19 August 2019
Ethics approval and consent to participate
: Approval of the study protocol (The Flatiron Health Analytic Database; protocol #15–159) by the New England Institutional Review Board, a WIRB-Copernicus company, was obtained prior to study conduct, and included a waiver of informed consent.
: Not applicable.
: PL, GC, BA, and MDT report employment with, and stock ownership in, Genentech, Inc.DK, NN, RS, RR, MGT, and NJM report employment with Flatiron Health, Inc., which is an independent subsidiary of the Roche Group. NJM, MGT, NN, RR, RS, and DK report equity interest in Flatiron and Roche.